Alumis (ALMS) grants Chief Scientific Officer 216,675 stock options

Rhea-AI Filing Summary

Alumis Inc. reported a stock option grant to Chief Scientific Officer David M. Goldstein. On January 26, 2026, he received an option to buy 216,675 shares of common stock at an exercise price of $26.31 per share, held as a direct derivative position.

According to the vesting terms, 25% of the shares underlying this option vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on his continued service under the company’s 2024 Equity Incentive Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goldstein David M

(Last) (First) (Middle)

C/O ALUMIS INC.

280 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALUMIS INC. [ ALMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$26.31	01/26/2026		A		216,675		(1)	01/25/2036	Common Stock	216,675	$0	216,675	D

Explanation of Responses:

1. 25% of the shares underlying this option vest on January 26, 2027, and the remaining shares vest in equal monthly installments thereafter over the following 36 months, subject to acceleration and the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan) to the Issuer on each such vesting date.

	/s/ Sanam Pangali, Attorney-in-Fact	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Alumis (ALMS) disclose in this Form 4 filing?

Alumis disclosed a stock option grant to Chief Scientific Officer David M. Goldstein. He received options over 216,675 common shares at a $26.31 exercise price, recorded as a direct derivative holding following the January 26, 2026 grant date.

How many stock options did Alumis grant to its Chief Scientific Officer?

Alumis granted Chief Scientific Officer David M. Goldstein stock options over 216,675 shares of common stock. These options give him the right to buy shares at a fixed exercise price if vesting and continued service conditions under the 2024 Equity Incentive Plan are satisfied.

What is the exercise price of the Alumis stock options reported for ALMS?

The stock options reported for Alumis carry an exercise price of $26.31 per share. This means David M. Goldstein can purchase up to 216,675 Alumis common shares at $26.31 if and when the options vest and are exercised.

When do the Alumis (ALMS) stock options for the CSO start vesting?

Vesting for the reported Alumis stock options begins on January 26, 2027. On that date, 25% of the underlying 216,675 shares vest, with the remaining shares vesting in equal monthly installments over the subsequent 36 months, subject to continued service.

What ongoing service conditions apply to the Alumis CSO’s stock options?

The options are subject to the reporting person’s Continuous Service to Alumis under its 2024 Equity Incentive Plan. After 25% vests on January 26, 2027, the remaining shares vest monthly over 36 months only if he remains in qualifying service on each vesting date.

Is the Alumis Chief Scientific Officer’s stock option holding direct or indirect?

The Form 4 identifies the stock option holding as direct. All 216,675 derivative securities reported following the transaction are listed with a direct ownership form, and no footnote assigns voting or investment power to any separate trust, partnership, or other entity.